Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: The impact of leukofiltered cellular blood product transfusions

Journal of Thoracic and Cardiovascular Surgery

Volumn 133, Issue 6, 2007, Pages 1612-1619

  Drakos, Stavros G ^a   Stringham, James C ^a,c,d   Long, James W ^a,b   Gilbert, Edward M ^a,d   Fuller, Thomas C ^a,d   Campbell, Beverly K ^a,b   Horne, Benjamin D ^a,b   Hagan, Mary E ^a,c   Nelson, Karl E ^a,b   Lindblom, Judy M ^b   Meldrum, Patty A ^d   Carlson, Joanne F ^a,d   Moore, Stephanie A ^a,b   Kfoury, Abdallah G ^a,b   Renlund, Dale G ^a,b,d  

^a Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program   (United States)

^b LDS HOSPITAL   (United States)

^c and Clinical Center   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; HLA ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; FEMALE; HEART ASSIST DEVICE; HEART TRANSPLANTATION; HUMAN; KAPLAN MEIER METHOD; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIZATION;

BLOOD TRANSFUSION; CHI-SQUARE DISTRIBUTION; FEMALE; HEART-ASSIST DEVICES; HLA ANTIGENS; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC;

EID: 34249027113     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2006.11.062     Document Type: Article

References (28)

1. US Organ Procurement and Transplantation Network, US Department of Health and Human Services. 2004 annual report (2004), US Government Printing Office, Washington, DC 11-19
2. Frazier O.H., Rose E.A., Oz M.C., Dembitsky W., McCarthy P., Radovancevic B., et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 122 (2001) 1189-1195
3. Massad M.G., Cook D.J., Schmitt S.K., Smedira N.G., McCarthy J.F., Vargo R.L., et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 64 (1997) 1120-1125
4. McKenna Jr. D.H., Eastlund T., Segall M., Noreen H.J., and Park S. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant 21 (2002) 1218-1224
5. Smith J.D., Danskine A.J., Laylor R.M., Rose M.L., and Yacoub M.H. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl Immunol 1 (1993) 60-65
6. Lavee J., Kormos R.L., Duquesnoy R.J., Zerbe T.R., Armitage J.M., Vanek M., et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 10 (1991) 921-930
7. Kobashigawa J.A., Sabad A., Drinkwater D., Cogert G.A., Moriguchi J.D., Kawata N., et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation?. Circulation 94 9 Suppl (1996) II294-II297
8. Moazami N., Itescu S., Williams M.R., Argenziano M., Weinberg A., and Oz M.C. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant 17 (1998) 876-880
9. Stringham J.C., Bull D.A., Fuller T.C., Kfoury A.G., Taylor D.O., Renlund D.G., et al. Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. J Heart Lung Transplant 18 (1999) 160-165
10. John R.J., Lietz K., Burke E., Ankersmit J., Mancini D., Suciu-Foca N., et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 100 19 Suppl (1999) II229-II235
11. Fauchet R., Genetet B., Gueguen M., Leguerrier A., Rioux C., and Logeais Y. Transfusion therapy and HLA antibody response in patients undergoing open heart surgery. Transfusion 22 (1982) 320-322
12. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 337 (1997) 1861-1869
13. Goldstein D.J., Seldomridge J.A., Chen J.M., Catanese K.A., DeRosa C.M., Weimberg A.D., et al. Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. Ann Thorac Surg 59 (1995) 1063-1068
14. Banbury M.K., Brizzio M.E., Rajeswaran J., Lytle B.W., and Blackstone E.H. Transfusion increases the risk of postoperative infection after cardiovascular surgery. J Am Coll Surg 202 (2006) 131-138
15. Brand A. Immunologic aspects of blood transfusions. Transplant Immunol 10 (2002) 183-190
16. Claas F.H., Roelen D.L., van Rood J.J., and Brand A. Modulation of the alloimmune response by blood transfusions. Transfus Clin Biol 8 (2001) 315-317
17. Opelz G., Vanrenterghem Y., Kirste G., Gray D.W., Horsburgh T., LaChance J.G., et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 63 (1997) 964-967
18. Wheatley T.J., Veitch P.S., Horsburgh M.L., and Bell P.R. Transfusion-induced immunosuppression: abrogation by leukodepletion. Transplant Proc 29 (1997) 2962-2963
19. Fernandez F.G., Jaramillo A., Ewald G., Rogers J., Pasque M.K., Mohanakumar T., et al. Blood transfusions decrease the incidence of acute rejection in cardiac allograft recipients. J Heart Lung Transplant 24 7 Suppl (2005) S255-S261
20. Lagaaij E.L., Hennemann P.H., Ruigrok M., DeHann M.W., Persijn G.G., Termijtelen A., et al. Effect of one-HLA-DR antigen matched and completely HLA-DR mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 321 (1989) 701-705
21. + regulatory T cell: a potential explanation for the blood-transfusion effect. Transplantation 76 (2003) 449-455
22. Williams Jr. R.C., Malone C.C., and Kao K.J. IgM rheumatoid factors react with human class I HLA molecules. J Immunol 156 (1996) 1684-1694
23. Ohto H., Yasuda H., Yokota M., Matsuoka T., and Nomizu T. HLA antibodies after transfusions of FFP. Transfusion 40 (2000) 613
24. Itescu S., Ankersmit J.H., Kocher A.A., and Schuster M.D. Immunobiology of left ventricular assist devices. Prog Cardiovasc Dis 43 (2000) 67-80
25. Rafii S., Oz M.C., Seldomridge J.A., Ferris B., Asch A.S., Nachman R.L., et al. Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices. Ann Thorac Surg 60 (1995) 1627-1632
26. Schuster M., Kicker A., John R., Hoffman M., Ankersmit J., Lietz K., et al. B-cell activation and allosensitization after left ventricular assist device implantation is due to T-cell activation and CD40 ligand expression. Hum Immunol 63 (2002) 211-220
27. Baran D.A., Gass A.L., Galin I.D., Zucker M.J., Arroyo L.H., Goldstien D.J., et al. Lack of sensitization and equivalent post-transplant outcomes with the Novacor left ventricular assist device. J Heart Lung Transplant 24 (2005) 1886-1890
28. Kumpati G.S., Cook D.J., Blackstone E.H., Rajeswaran J., Abdo A.S., Young J.B., et al. HLA sensitization in ventricular assist devices recipients: does type of device make a difference?. J Thorac Cardiovasc Surg 127 (2004) 1800-1807